EDP-305

EDP-305 is a non-bile acid farnesoid X receptor (FXR) agonist developed by Enanta Pharmaceuticals for non-alcoholic fatty liver disease. According to preclinical research CYP3A4 is the main enzyme used to metabolize the drug and there is a low potential for drug interactions.